A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Status:
Completed
Trial end date:
2011-05-25
Target enrollment:
Participant gender:
Summary
This single arm study will evaluate the benefit of adding MabThera to standard induction
chemotherapy in patients with newly diagnosed mantle cell lymphoma. The safety and
tolerability of a MabThera-containing first line regimen will also be assessed. All patients
will receive MabThera (375mg/m2 iv) every 3 weeks for 8 cycles, in combination with standard
chemotherapy. The anticipated time on study treatment is 3-12 months, and the target sample
size is <100 individuals.